GAIT DISTURBANCE and Dilaudid

PatientsVille

Find and Compare Side Effects

GAIT DISTURBANCE Symptoms and Causes

Multiple sclerosis (MS) is a nervous system disease that affects your brain and spinal cord. It damages the myelin sheath, the material that surrounds and protects your nerve cells. This damage slows down or blocks messages between your brain and your body, leading to the symptoms of MS. They can include

Visual disturbances

Muscle weakness

Trouble with coordination and balance

Sensations such as numbness, prickling, or "pins and needles"

Thinking and memory problems

No one knows what causes MS. It may be an autoimmune disease, which happens when your immune system attacks healthy cells in your body by mistake. Multiple sclerosis affects women more than men. It often begins between the ages of 20 and 40. Usually, the disease is mild, but some people lose the ability to write, speak, or walk.

There is no single test for MS. Doctors use a medical history, physical exam, neurological exam, MRI, and other tests to diagnose it. There is no cure for MS, but medicines may slow it down and help control symptoms. Physical and occupational therapy may also help.

GAIT DISTURBANCE Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.

Association between pain scale change and TBW/BMI; Association between change in pain at 15 minutes,; pain treatment satisfaction at 30 min; adverse events (low SatO2<92%, SBP< 90mmHg); side effects (nausea, vomit, itching); influence of gender on the association between TBW, BMI and response to iv hydromorphone; influence of race/ethnicity, and genetic factors on the association between TBW, BMI and response to iv hydromorphone; influence of genetic factors on the association between TBW, BMI and response to iv hydromorphone; influence of age on the association between TBW/BMI and response to hydromorphone

The primary objective is to find the optimal dose of IT hydromorphone for pain relief following C/S.; A secondary objective is to define the incidence and severity of hydromorphone's side effects.; A secondary objective is to determine the duration of analgesia

Opioid Blockade Following Administration of 0, 6, or 18 mg Intramuscular (IM) Hydromorphone As Measured Using the Subjective Opioid Effects Rating for the Question "Do you like the drug?" Visual Analog Scale (VAS); Reinforcing Effects Of the Daily Randomized Hydromorphone Challenge as Measured by the Mean Hydromorphone Break Point Value; Relationship between plasma concentration and predicted mu opioid receptor occupancy of buprenorphine and both the blockade of the subjective effects of hydromorphone post injection of buprenorphine 300 mg (RBP-6000); Summary of Participants with Adverse Events; Correlation between the opioid blockade subjective effect when participants are asked "Do you feel any drug effect?" and simulated mu opioid receptor occupancy; Correlation between the opioid blockade subjective effect when participants are asked "Does the drug have any good effects?" and simulated mu opioid receptor occupancy; Correlation between the opioid blockade subjective effect when participants are asked "Do you like the drug?" and simulated mu opioid receptor occupancy; Correlation between the opioid blockade subjective effect when participants are asked "Do you feel sedated?" and simulated mu opioid receptor occupancy; Correlation between the opioid blockade subjective effect when participants are asked "How high are you right now?" and simulated mu opioid receptor occupancy; Correlation between the opioid blockade subjective effect when participants are asked "Does the drug have any bad effects?" and simulated mu opioid receptor occupancy

Decline additional pain medication; Number of participants with hypotension (SBP < 90 mmHg); Number of participants with bradycardia (HR < 50/min); Number of patients with nausea and vomiting; Number of participants with pruritus; Number of participants needing naloxone as a reversal agent

If you think you may have a medical emergency, call your doctor or 911 immediately.

By accessing this website, you are indicating your acknowledgement and acceptance of these Terms of Use. These Terms of Use are subject to change by WinFirst LLC at any time in its discretion. Your use of WinFirst LLC Site after such changes are implemented constitutes your acknowledgement and acceptance of the changes. Please consult these Terms of Use regularly.
PatientsVille.com does not provide medical advice, diagnosis or treatment. The information contained on PatientsVille.com site has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of adverse drug reactions or for establishing or changing of patient treatments.